NorthWest Biotherapeutics Inc (NWBO)

[abeta]

~25-35 % survival over 5 years from diagnosis in vaccinated GBM patients vs a historical rate of ~ 5%

Published: Sep 01, 2020

Immunomic Therapeutics Announces Publication of Results
from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM

Three separate clinical trials conducted by Drs. Mitchell and Sampson utilized Cytomegalovirus specific dendritic cell vaccines in patients with newly diagnosed glioblastoma.

The three small studies (total n = 26; NCT#s 00639639, 2366728) revealed that overall 5-year survival increased from a historical low of 5% to 25%. However, in two of the studies, vaccination site pre-conditioning with either Td or GM-CSF:

This data is preliminary, and additional studies are needed.

https://www.biospace.com/article/releases/immunomic-therapeutics-announces-publication-of-results-from-3-attac-studies-of-cmv-specific-dendritic-cell-vaccines-for-the-treatment-of-gbm/